Cargando…

Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2

Outbreak of coronavirus disease 2019 occurred in Wuhan and has rapidly spread to almost all parts of world. GB-1, the herbal formula from Tian Shang Sheng Mu of Chiayi Puzi Peitian Temple, is used for the prophylaxis of SARS-CoV-2 in Taiwan. In this study, we investigated that the effect of GB-1 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Ching-Yuan, Lin, Yu-Shih, Yang, Yao-Hsu, Shu, Li-Hsin, Cheng, Yu-Ching, Liu, Hung Te
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773841/
https://www.ncbi.nlm.nih.gov/pubmed/33390952
http://dx.doi.org/10.3389/fphar.2020.584158
_version_ 1783630134798974976
author Wu, Ching-Yuan
Lin, Yu-Shih
Yang, Yao-Hsu
Shu, Li-Hsin
Cheng, Yu-Ching
Liu, Hung Te
author_facet Wu, Ching-Yuan
Lin, Yu-Shih
Yang, Yao-Hsu
Shu, Li-Hsin
Cheng, Yu-Ching
Liu, Hung Te
author_sort Wu, Ching-Yuan
collection PubMed
description Outbreak of coronavirus disease 2019 occurred in Wuhan and has rapidly spread to almost all parts of world. GB-1, the herbal formula from Tian Shang Sheng Mu of Chiayi Puzi Peitian Temple, is used for the prophylaxis of SARS-CoV-2 in Taiwan. In this study, we investigated that the effect of GB-1 and the index compounds of GB-1 on the ACE2 and TMPRSS2 expression through in vitro and in vivo study. In our result, GB-1 can inhibit ACE2 and TMPRSS2 protein expression in HepG2 cells, 293T cells, and Caco-2 cells without cytotoxicity. For the mouse model, GB-1 treatment could decrease ACE2 and TMPRSS2 expression levels of the lung and kidney tissue without adverse effects, including nephrotoxicity and hepatotoxicity. In the compositions of GB-1, 0.5–1 mg/ml of Glycyrrhiza uralensis Fisch. ex DC. extract could not inhibit ACE2 mRNA and protein expression in HepG2 cells. In addition, theaflavin-3-gallate could inhibit protein expression of ACE2 and TMPRSS2 without significant cytotoxicity. Our results suggest that GB-1 and theaflavin-3-gallate could act as potential candidates for prophylaxis or treatment of SARS-CoV-2 infection through inhibiting protein expression of ACE2 and TMPRSS2 for the further study.
format Online
Article
Text
id pubmed-7773841
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77738412021-01-01 Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2 Wu, Ching-Yuan Lin, Yu-Shih Yang, Yao-Hsu Shu, Li-Hsin Cheng, Yu-Ching Liu, Hung Te Front Pharmacol Pharmacology Outbreak of coronavirus disease 2019 occurred in Wuhan and has rapidly spread to almost all parts of world. GB-1, the herbal formula from Tian Shang Sheng Mu of Chiayi Puzi Peitian Temple, is used for the prophylaxis of SARS-CoV-2 in Taiwan. In this study, we investigated that the effect of GB-1 and the index compounds of GB-1 on the ACE2 and TMPRSS2 expression through in vitro and in vivo study. In our result, GB-1 can inhibit ACE2 and TMPRSS2 protein expression in HepG2 cells, 293T cells, and Caco-2 cells without cytotoxicity. For the mouse model, GB-1 treatment could decrease ACE2 and TMPRSS2 expression levels of the lung and kidney tissue without adverse effects, including nephrotoxicity and hepatotoxicity. In the compositions of GB-1, 0.5–1 mg/ml of Glycyrrhiza uralensis Fisch. ex DC. extract could not inhibit ACE2 mRNA and protein expression in HepG2 cells. In addition, theaflavin-3-gallate could inhibit protein expression of ACE2 and TMPRSS2 without significant cytotoxicity. Our results suggest that GB-1 and theaflavin-3-gallate could act as potential candidates for prophylaxis or treatment of SARS-CoV-2 infection through inhibiting protein expression of ACE2 and TMPRSS2 for the further study. Frontiers Media S.A. 2020-12-17 /pmc/articles/PMC7773841/ /pubmed/33390952 http://dx.doi.org/10.3389/fphar.2020.584158 Text en Copyright © 2020 Wu, Lin, Yang, Shu, Cheng and Liu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wu, Ching-Yuan
Lin, Yu-Shih
Yang, Yao-Hsu
Shu, Li-Hsin
Cheng, Yu-Ching
Liu, Hung Te
Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2
title Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2
title_full Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2
title_fullStr Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2
title_full_unstemmed Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2
title_short Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2
title_sort potential simultaneous inhibitors of angiotensin-converting enzyme 2 and transmembrane protease, serine 2
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773841/
https://www.ncbi.nlm.nih.gov/pubmed/33390952
http://dx.doi.org/10.3389/fphar.2020.584158
work_keys_str_mv AT wuchingyuan potentialsimultaneousinhibitorsofangiotensinconvertingenzyme2andtransmembraneproteaseserine2
AT linyushih potentialsimultaneousinhibitorsofangiotensinconvertingenzyme2andtransmembraneproteaseserine2
AT yangyaohsu potentialsimultaneousinhibitorsofangiotensinconvertingenzyme2andtransmembraneproteaseserine2
AT shulihsin potentialsimultaneousinhibitorsofangiotensinconvertingenzyme2andtransmembraneproteaseserine2
AT chengyuching potentialsimultaneousinhibitorsofangiotensinconvertingenzyme2andtransmembraneproteaseserine2
AT liuhungte potentialsimultaneousinhibitorsofangiotensinconvertingenzyme2andtransmembraneproteaseserine2